Lactic acid bacteria: benefits, dosage, contraindications

Mis à jour le

The organism maintains symbiotic relationships with prokaryotic organisms, some of which are known as "probiotics". It is estimated that the intestines harbor 1014 microbes representing more than 1,000 different species, including yeasts, mainly Candida albicans (<0.1% of the microbiota). The term "probiotic", coined in 1965, comes from Greek and means "for life." In the gastrointestinal tract, these organisms help metabolize food and maintain intestinal health. A probiotic product must contain living microorganisms which, when administered in sufficient quantities, are intended to confer a health benefit to the host. As early as 1907, Metchnikoff, a Nobel Prize laureate, popularized the idea that fermented dairy products could beneficially alter the gastrointestinal microflora. He believed that many diseases, and even aging itself, were caused by the putrefaction of proteins in the intestine by intestinal bacteria. These microorganisms provide many health benefits by preventing colonization of the digestive tract by pathogenic microorganisms and by performing a number of biochemical functions, such as deconjugation and dehydroxylation of bile acids, conversion of bilirubin to urobilinogen, production of short-chain fatty acids, and metabolism of cholesterol to coprostanol. In addition, the microbiota modulates immune function, improves gastrointestinal motility and intestinal barrier function, enhances digestion and nutrient absorption, metabolizes xenobiotics (for example, phytoestrogens), and produces vitamins K, B1, B2, B6, and B12. The gastrointestinal microbiota is rather resistant to change and remains fairly constant in adults, although research has shown that components such as prebiotics and probiotics can beneficially modulate the intestinal microflora, while antibiotics, chemotherapy, stress, and a Western diet can negatively impact the ecosystem. Probiotics can be obtained by consuming fermented foods, as well as in foods such as cheese, kefir, kimchi, kombucha, miso, sauerkraut, and yogurt, or in supplements. It is important to note, however, that probiotic organisms must possess certain characteristics in order to exert maximal therapeutic effects. Among these characteristics: - Stability to gastric acids and bile salts; - The ability to adhere to the intestinal mucosa; - The ability to colonize the intestinal tract. Bacteria are named and classified, for example the genus Lactobacillus, bifidobacteria. A strain is an even more specific classification that divides members of the same species into subgroups based on several properties that a bacterial strain possesses and that distinguish it from other members of that species. It is difficult to establish clear signs of deficiency because symptoms can vary greatly. Local signs and symptoms of a disruption of the intestinal microflora leading to an imbalance (intestinal dysbiosis) include bloating, flatulence, abdominal pain, diarrhea and/or constipation, and fungal overgrowth (such as Candida). An imbalance of the gastrointestinal microflora can be caused by the use of antibiotics, digestive tract infections, stress, and dietary factors. Administration of probiotics is often used as a means to restore this microflora imbalance. In general, these probiotic strains could contribute to strengthening immunity, while protecting the digestive system against certain bacterial infections.

Other name(s) 

Probiotics

Family or group: 

Probiotics

Active ingredients:

Lactobacilli

Bifidobacteria


Indications

Scoring methodology

EFSA approval.

Several randomized, double-blind, controlled clinical trials (> 2), including a significant number of patients (>100), with consistently positive conclusions for the indication.
Several randomized, double-blind, controlled clinical trials (> 2), including a significant number of patients (>100), with positive conclusions for the indication.
One or more randomized studies, or several cohorts or epidemiological studies, with positive conclusions for the indication.
Clinical studies exist but are uncontrolled, with conclusions that may be positive or conflicting.
No clinical studies to date that can demonstrate the indication.


Diarrhea
✪✪✪✪✪

Diarrhea can be caused by infections (viruses, parasites, bacteria), including acute diarrhea (gastroenteritis) and traveler's diarrhea caused by E. coli. Studies show that consuming at least 10 IU of lactic ferments (mixtures of lactobacilli and bifidobacteria) can prevent and/or treat (reduce the duration of) these diarrheas. Some clinical research shows that taking 250 mL of fermented milk containing a minimum of Lactobacillus rhamnosus GG 108 colony-forming units (CFU)/mL, Lactobacillus acidophilus La-5 107 CFU/mL, and Bifidobacterium Bb-12 108 CFU/mL orally every day for 14 days reduces the relative risk of antibiotic-associated diarrhea by 79% compared with the same dairy product containing heat-killed bacteria. Other clinical research shows that taking 49 grams of fermented milk containing at least 50 x 109 CFU of Lactobacillus acidophilus CL1285 and Lactobacillus casei (Bio-K+ CL1285, Bio-K+ International Inc) orally every day for 2 days, followed by 98 grams per day until the end of antibiotic treatment, reduces the relative percentage of patients suffering from antibiotic-associated diarrhea by 55% compared with placebo in hospitalized patients receiving systemic antibiotics. IU: billions of CFU

Posologie

posologieOrally

posologie108 IU

formulationfermented milk


Vaginal infections
✪✪✪✪✪

Vaginal infections (bacterial or Candida) are characterized by an imbalance of the vaginal flora. Studies have shown that standard treatments are more effective when accompanied by supplementation with lactic acid bacteria. Consumption of lactic acid bacteria reduces the risk of vaginal infections in pregnant women by 81%. A meta-analysis of 10 clinical studies conducted in patients with bacterial vaginosis shows that taking a probiotic alone or with antibiotics increases the chances of cure by 39% around day 30 after the intervention, compared with the control group. Various species of probiotics have been evaluated; it is not known exactly which species, if any, might be the most beneficial.

Posologie

posologieOrally

formulationFermented milk


Eczema
✪✪✪✪✪

The intestinal microflora plays a major protective role against the development of allergy because it reduces the transport of antigens across the intestinal mucosa and helps induce oral tolerance. Consequently, probiotics may have a protective role in the prevention and/or management of atopic dermatitis and eczema due to their proposed actions. A number of clinical trials have investigated probiotic therapy to prevent the development of atopic eczema, and some have evaluated the effectiveness of probiotic therapy in the treatment of eczema. Pelucchi et al (2012) performed a meta-analysis of randomized controlled trials to determine whether the use of probiotics during pregnancy and early life reduces the incidence of atopic eczema and IgE-associated atopic eczema in infants and young children. Eighteen publications based on 14 studies were included in the analysis. The meta-analysis showed that probiotic use reduced the incidence of atopic dermatitis. Although the overall evidence supports the use of probiotics to reduce the incidence of atopic dermatitis in infants and young children, some strains were not effective. For example, the LAVRI-A1 strain of Lactobacillus acidophilus was not effective at reducing the incidence of developing atopic dermatitis. In another randomized, placebo-controlled, double-blind trial, the efficacy of Lactobacillus paracasei F-19 was evaluated. In this trial, the probiotic was administered to the infant (n = 179) directly at the time of weaning (mixed with food). The infants consumed the probiotic (1 × 10^8 CFU/day) from 4 to 13 months. Probiotic supplementation resulted in a significant reduction in cumulative incidence of eczema at 13 months and an improvement in the Th1/Th2 ratio. In another double-blind trial, women (n = 415) were randomized to receive either a placebo or a probiotic milk (containing Lactobacillus rhamnosus GG, Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12) from 36 weeks' gestation to 3 months postnatal during breastfeeding. Probiotic milk reduced the likelihood that the child would develop atopic dermatitis at age 6 by about 52% compared with placebo milk. No significant effect was observed on rates of asthma or atopic sensitization.

Posologie

posologieOral administration

posologie108 IU

formulationhas been fermented


Cold
✪✪✪✪✪

A clinical study conducted among children aged 3 to 6 years attending daycare shows that taking a fermented dairy product containing Lactobacillus casei at a dose of 200 g per day for 3 months reduces the risk of developing a cold, the most common upper respiratory tract infection in these children, by about 18.5% compared with a control dairy product. In healthy, middle-aged male office workers, a preliminary clinical study shows that consumption of a fermented milk containing Lactobacillus casei Shirota for 12 weeks reduces the incidence and duration of the common cold by 59% compared with a control milk.

Posologie

posologieOral administration

formulationFermented milk


Helicobacter pylori infection
✪✪✪✪✪

Oral probiotics, when added to most standard H. pylori eradication regimens, appear to be beneficial for improving eradication rates. Several meta-analyses show that taking probiotics in conjunction with standard H. pylori eradication therapy can increase eradication rates by 1.1 to 2 times compared with standard eradication therapy alone. Clinical research shows that Saccharomyces boulardii, Lactobacillus species, and bifidobacterial species may improve eradication rates. However, this effect appears to depend on the probiotic species or strain used, as well as on the eradication regimen. A meta-analysis shows the greatest benefit is obtained when a probiotic is added to quadruple therapies containing bismuth. Some research indicates that taking a combination of lactobacilli and bifidobacteria at the same time as the eradication treatment can double the eradication rate, while taking a probiotic containing lactobacilli alongside eradication therapy improves the eradication rate by 1.2. However, the effectiveness of lactobacillus appears to depend on the eradication regimen. Taking lactobacillus at the same time as an eradication regimen composed of a proton pump inhibitor, clarithromycin, and amoxicillin appears to improve eradication rates, but taking lactobacillus with a quadruple therapy, sequential therapy, or a therapy that does not include amoxicillin does not appear to improve eradication. Similarly, taking lactobacilli without antibiotics does not improve eradication rates in adults. Research on the use of yogurts or dairy products containing probiotics is more mixed.

Posologie

posologieOrally

formulationfermented

Long-term administration of probiotics to asymptomatic pre-school children for either the eradication or the prevention of Helicobacter pylori infection
Adjuvant probiotics improve the eradication effect of triple therapy for Helicobacter pylori infection
Systematic review with meta-analysis: Saccharomyces boulardii supplementation and eradication of Helicobacter pylori infection
Effect of fermented milk-based probiotic preparations on Helicobacter pylori eradication: a systematic review and meta-analysis of randomized-controlled trials.
Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication.
Efficacy and safety of probiotics in eradicating Helicobacter pylori: A network meta-analysis
Lactobacillus gasseri Suppresses the Production of Proinflammatory Cytokines in Helicobacter pylori-Infected Macrophages by Inhibiting the Expression of ADAM17
Antagonistic activities of lactobacilli against Helicobacter pylori growth and infection in human gastric epithelial cells
Effect of Lactobacillus acidophilus and Bifidobacterium bifidum supplementation to standard triple therapy on Helicobacter pylori eradication and dynamic changes in intestinal flora.
Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis
Suppressive effect of Lactobacillus gasseri OLL 2716 (LG21) on Helicobacter pylori infection in humans
Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy
Effects of multistrain probiotic-containing yogurt on second-line triple therapy for Helicobacter pylori infection
Efficacy of Probiotic Supplementation Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Controlled Trials
Antagonistic activity of probiotic lactobacilli and bifidobacteria against entero- and uropathogens
Lactobacillus reuteri strain combination in Helicobacter pylori infection: a randomized, double-blind, placebo-controlled study
Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy.
Effect of pretreatment with Lactobacillus gasseri OLL2716 on first-line Helicobacter pylori eradication therapy
Lactobacillus gasseri OLL2716 as a probiotic in clarithromycin-resistant Helicobacter pylori infection

Irritable bowel syndrome
✪✪✪✪✪

Several species of probiotics have been evaluated to improve IBS symptoms. In general, clinical research shows that probiotics moderately improve IBS symptoms, particularly abdominal pain. The best evidence to date concerns a specific strain of bifidobacteria, called Bifidobacterium infantis 35624 (Align or Bifantis). Clinical research shows that taking this strain reduces abdominal pain, bloating and difficulty with bowel movements in the week following treatment. Clinical research also shows that daily intake of Bacillus coagulans for 56 to 90 days improves quality of life and reduces bloating, vomiting, abdominal pain and stool frequency compared with placebo. The American College of Gastroenterology conditionally recommends the use of probiotics, particularly combination probiotics, to improve overall symptoms, as well as bloating and flatulence, in patients with IBS.

Posologie

posologieOrally

formulationfermented milk


Respiratory infections
✪✪✪✪✪

Probiotics may be effective in strengthening the immune system and combating seasonal respiratory infections.nnA double-blind, placebo-controlled study was conducted on 479 healthy individuals for more than three months, who orally took a mixture of Lactobacillus. gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5. The aim was to clinically evaluate the influence of these probiotic strains in relieving the severity of symptoms and the duration of colds.nnThe results revealed that the group treated with probiotics showed a reduced duration of symptoms with milder symptoms. In addition, their cytotoxic T lymphocytes and CD8+ cells were significantly strengthened compared with the control group. nnThe study thus shows that L. gasseri, combined with other lactic cultures, reduces the duration and severity of symptoms of seasonal viral respiratory illnesses. nnPreliminary studies suggest that consumption of lactobacilli reduces the incidence of the common cold by about 12% in adults and reduces the incidence of respiratory disorders and infections in patients with cystic fibrosis from 37% to 3%. Certain strains of lactobacilli (rhamnosus GG) would notably reduce pulmonary exacerbations and hospital admission in children suffering from cystic fibrosis, notably through an anti-inflammatory action.nn

Posologie

posologieOrally

formulationwas fermented


Infant colic
✪✪✪✪✪

Clinical research shows that L. reuteri DSM 17938 may be beneficial for the TREATMENT of colic in breastfed infants. Administration of this specific strain for 21 to 28 days can reduce daily crying time in breastfed infants. Symptoms appear to improve within a week following treatment. In some clinical studies, the reduction in colic symptoms was greater in infants who received this strain than with simethicone 60 mg once or twice daily over a 28-day period. A meta-analysis of the available clinical research shows that probiotics do not appear to PREVENT the development of colic in infants. Research evaluating other Lactobacillus species or other probiotics is lacking.

Posologie

posologieOrally

formulationhas been fermented


Constipation
✪✪✪✪✪

A meta-analysis of clinical research in adults with functional constipation shows that taking probiotics increases stool frequency compared with placebo.nnA specific probiotic species, L. reuteri DSM 17938 (BioGaia), has the strongest evidence of benefit. Other single-strain or combined probiotic products containing species of lactobacilli and/or bifidobacteria have also shown benefits in clinical research. Overall, the evidence for using probiotics to reduce constipation symptoms in adults is promising.nnHowever, because most available studies evaluate different probiotic strains, further research is needed to confirm which strains might be most beneficial.nnHowever, research conducted in children shows that taking probiotics does not improve constipation symptoms compared with placebo, as demonstrated by a meta-analysis of four clinical trials.nn

Posologie

posologieOrally

formulationwas fermented


Allergic rhinitis
✪✪✪✪✪

Some clinical research shows that fermented milk may reduce certain symptoms of allergic rhinitis in adults. The consumption of 100 ml of heat‑treated fermented milk containing the L‑92 strain of Lactobacillus acidophilus (3 x 10^10 colony-forming units (CFU)/100 ml) per day for 8 weeks appears to reduce subjective nasal symptoms, but not ocular symptoms, compared with placebo in patients with allergic rhinitis. A clinical study conducted in adults suffering from allergic rhinitis caused by Japanese cedar pollen shows that the consumption of 80 ml of fermented milk containing the Shirota strain of Lactobacillus casei (4 x 10^8 colony-forming units (CFU)/ml) per day for 8 weeks does not improve allergic nasal symptoms compared with consumption of non‑fermented milk. Other studies suggest that fermented milk may also decrease the incidence of allergic rhinitis in children and adolescents. A clinical study conducted in preschool‑aged children with allergic rhinitis shows that taking 100 ml of fermented milk containing Lactobacillus casei, Lactobacillus bulgaricus and Streptococcus thermophilus orally once daily for 12 months reduces the annual number of rhinitis episodes by 1.6 compared with placebo. While other clinical research shows that consuming 200 to 400 ml of fermented milk containing Streptococcus thermophilus and Lactobacillus bulgaricus for 30 days does not improve allergic rhinitis symptoms in children and adolescents with allergic rhinitis, fortifying the product with Lactobacillus paracasei improves quality of life compared with consuming fermented milk that does not contain Lactobacillus paracasei. Fermented milk has also been studied for the prevention of allergic rhinitis in newborns. Clinical research conducted in pregnant women shows that consuming 250 ml of fermented milk containing Lactobacillus rhamnosus GG, Lactobacillus acidophilus and Bifidobacterium animalis during pregnancy, from the 36th week of gestation until 3 months after delivery, does not reduce the risk that the child will develop allergic rhinitis at age 6 years, compared with placebo milk. 

Posologie

posologieOrally

formulationhas fermented


Chronic inflammatory bowel diseases
✪✪✪✪✪

Probiotics are used as an adjuvant therapy for Crohn's disease and ulcerative colitis. Overall, current research indicates a limited role for probiotics in Crohn's disease; results for ulcerative colitis are more promising, and there appears to be a beneficial effect on pouchitis (inflammation of the ileal pouch). Meta-analyses of clinical research show that taking probiotics increases the remission rate by a factor of 1.4 to 1.8 compared with placebo. The strongest evidence concerns a probiotic formulation containing species of lactobacilli, bifidobacteria, and streptococci (VSL#3). A meta-analysis also suggests that combination products containing bifidobacteria may be more effective than probiotics that do not contain bifidobacteria. Although a meta-analysis of three clinical trials shows that taking probiotics prevents relapses in 40% more patients than taking a placebo, most clinical research shows that probiotics containing lactobacilli or bifidobacteria, including VSL#3, do not prevent relapses in patients in remission. Given that most available studies are small and of low quality and that some have shown no benefit for induction of remission or prevention of relapses, further research is needed to confirm which probiotics, if any, might be beneficial for this use.

Posologie

posologieOrally

formulationVSL#3


Properties


Gastroprotective

full-leaffull-leaffull-leaffull-leaf

It has been found that a number of probiotic strains increase mucin production in the intestine by increasing expression of the mucin gene, which provides a protective coating between the lumen and the intestinal epithelial cells. Probiotics are also able to directly strengthen the intestinal barrier. A strain of Lactobacillus plantarum (WCSF1) has been found to decrease paracellular intestinal permeability by increasing the relocalization of occludin and zonulin proteins to the tight junction between duodenal epithelial cells. Occludin and zonulin are essential for keeping the cells of the intestinal wall tightly connected. Other strains appear to improve barrier function by preserving the cytoskeletal architecture of enterocytes and by strengthening the protein structures of the tight junction. These strains should prove useful in the treatment and prevention of intestinal permeability.

Usages associés

Helicobacter pylori infection, irritable bowel syndrome

Antibacterial

full-leaffull-leaffull-leafempty-leaf

In vitro research suggests that fermented dairy products contain antimicrobial compounds that inhibit the growth of Salmonella and Shigella. The lactic bacteria present in fermented dairy products can release compounds that prevent pathogenic bacteria from colonizing the digestive tract. It is thought that the probiotic can prevent pathogenic bacteria from finding a place on host tissue to attach and grow. For example, lactobacilli adhere to and colonize the intestinal or urogenital tracts, reducing epithelial attachment by pathogenic bacteria. Lactobacilli are thought to achieve this in part by increasing epithelial mucus production and by competing with pathogens for binding sites on the mucosa. According to human studies, regular consumption of fermented milk may reduce potentially pathogenic bacteria in the upper respiratory tract.

Usages associés

Vaginal infections, respiratory infections, common cold

Immunomodulatory

full-leaffull-leaffull-leafempty-leaf

A body of evidence indicates that certain probiotic strains are capable of modulating the immune system at both systemic and mucosal levels. Some probiotic strains can influence the immune system, affecting epithelial cells (lining cells), dendritic cells, and natural killer cells. They can stimulate the production of immunoglobulin A (IgA) and increase the activities of natural killer cells and macrophages. In addition, dendritic cells located in the submucosal tissue can interact with these probiotics to promote a balanced immune response. This includes the maturation of dendritic cells and the regulation of helper T-cell responses (Th1, Th2, Th3/Tr1).

Usages associés

Eczema

Antiallergic

full-leaffull-leafempty-leafempty-leaf

Animal and human studies suggest that lactic acid bacteria, commonly found in fermented dairy products, attenuate allergic diseases. The mechanism may involve enhancement of Th1 immune responses in patients with high serum immunoglobulin E (IgE) concentrations. It should be noted that IgE plays a key role in allergies by triggering the release of histamine and other chemicals that cause allergic symptoms.

Usages associés

Eczema, Allergic rhinitis

Cardiovascular

full-leaffull-leafempty-leafempty-leaf

Alterations of the gut microflora induced by the ingestion of fermented milk can influence systemic lipid metabolism. Fermented milk formulations significantly reduce total cholesterol and low-density lipoprotein (LDL) levels in some hypercholesterolemic patients. The fermented milk bacteria that colonize the large intestine can ferment indigestible carbohydrates, leading to an increased production of short-chain fatty acids, which lower circulating cholesterol concentrations either by inhibiting hepatic cholesterol synthesis or by redistributing cholesterol from plasma to the liver. In addition, increased bacterial activity in the large intestine may promote the deconjugation of bile acids. Deconjugated bile acids are poorly absorbed by the intestinal mucosa and are excreted. Cholesterol, a precursor of bile acids, is then used to a greater extent for the de novo synthesis of bile acids.


Digestive effect

full-leaffull-leafempty-leafempty-leaf

There is evidence that probiotics containing certain bacterial strains can affect Helicobacter pylori infection or its activity and the emergence of upper gastrointestinal symptoms in adults and children. Human studies have shown that fermented milk may be effective in treating and maintaining remission of ulcerative colitis, pouchitis, irritable bowel syndrome, and constipation. Consumption of fermented milk increases the total number of Bifidobacterium and Lactobacillus in the feces or colon, and decreases clostridia and other pathogenic bacteria. Consumption of a fermented milk containing Bifidobacterium animalis DN-173 010 shortens colonic transit time in healthy women. However, the effect does not appear to be due to changes in fecal bacterial mass or secondary bile acids. Fermented dairy products have also been shown to slow gastric emptying.

Usages associés

Diarrhea, infant colic, constipation

Anti-inflammatory

full-leaffull-leafempty-leafempty-leaf

It has been shown that probiotic strains have anti-inflammatory effects via a number of different mechanisms. They can secrete metabolites with anti-inflammatory properties (anti–tumor necrosis factor-α [TNF-α] effects), they can interact with Toll-like receptors, downregulate the transcription of a number of genes encoding pro-inflammatory effectors, and upregulate the production of anti-inflammatory cytokines.

Usages associés

Chronic inflammatory bowel diseases

Anticancer

full-leafempty-leafempty-leafempty-leaf

In vivo and in vitro research shows antitumor activity of lactobacilli in colon cancer, and some epidemiological studies have indicated a reduced risk of breast cancer in women who consume fermented dairy products. In a study evaluating the effect of milk fermented by five bacterial strains (Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium animalis, Lactobacillus acidophilus and Lactobacillus paracasei) on the growth of breast cancer cells, all fermented dairy products showed growth inhibition, although Bifidobacterium infantis and Lactobacillus acidophilus were the most effective (85% inhibition after 9 days). It has been proposed that the mechanism involved a compound produced by the bacteria during the fermentation process or the microbial transformation of certain milk components into a biologically active form. Fermented milk has also been shown to increase the tumoricidal activity of natural killer cells.


Safe dosage

Adults aged 18 years and older: 1 IU

Probiotic doses are generally standardized in terms of the quantity of live bacteria per unit of volume. Each living bacterium is called a colony-forming unit, or CFU. 1 IU = 1 billion CFU (Colony Forming Unit). The minimum concentration of probiotic bacteria necessary to achieve therapeutic effects seems to depend somewhat on the strain, in that, for some strains (for example L. reuteri MM53), 10 million bacteria is a sufficient amount to produce beneficial effects, whereas for other strains, 1 billion viable CFU bacteria are necessary (for example L. rhamnosus GG). This situation makes it difficult to formulate firm dosing recommendations, because the minimum effective dose appears to differ by strain. Best practice is therefore to ensure that supplements contain bacteria at concentrations of >1 billion CFU per dose, unless research has shown that the specific strain contained in the supplement is effective at smaller amounts.

Pregnant woman:

The L. rhamnosus GG strain has been used with apparent safety during pregnancy, from 2 to 4 weeks before delivery. nnThe L. rhamnosus HN001 strain has been used with apparent safety from 14 to 16 weeks' gestation until 6 months after delivery. nnL. salivarius has been used with apparent safety from the diagnosis of gestational diabetes until delivery. nnCombinations of L. rhamnosus or L. paracasei with Bifidobacterium longum from 2 months before delivery until the breastfed infant is 2 months old have been used with apparent safety during pregnancy and breastfeeding. nnA combination of L. acidophilus, L. casei and Bifidobacterium bifidum has been used with apparent safety for 6 weeks starting from the 24th to the 28th week of gestation.nnThe safety of using other strains in pregnant women is unknown.nn

Breastfeeding woman:

The L. rhamnosus GG strain has been used with apparent safety in breastfeeding women for a period of up to six months. nnCombinations of L. rhamnosus or L. paracasei with Bifidobacterium longum from 2 months before delivery until the breastfed infant is 2 months old have been used with apparent safety during pregnancy and breastfeeding.nnThe safety of using other strains in breastfeeding women is unknown.nn

Child aged 1 to 18 years:

The L. rhamnosus GG strain has been used safely. L. acidophilus, L. brevis, L. johnsonii, and L. reuteri have been used safely for 12 weeks. A specific combination of probiotics containing strains of lactobacilli (some of these strains have been reclassified), Bifidobacterium, and Streptococcus salivarius (VSL#3, marketed as VIVOMIXX) has been used safely for one year in children aged 1 to 16 years. A specific probiotic combination containing L. acidophilus and Bifidobacterium animalis has been used safely for up to 6 months in children aged 3 to 5 years. A combination of L. acidophilus and Bifidobacterium bifidum has been used safely for 6 weeks. L. paracasei, L. fermentum, or a combination of the two species has been used with apparent safety for 3 months in children aged 1 to 18 years.

Infant up to 12 months:

Infants have safely consumed probiotics in drop form. See studies with BioGaia.


Precautions

Valvular heart disease: avoid

Patients with valvular heart disease who use probiotics containing lactobacillus may be at risk of endocardial inflammation. Cases of lactobacillus endocarditis have been reported in patients with valvular heart disease who used probiotics containing lactobacillus before dental surgery, upper endoscopy, or colonoscopy. Patients with valvular heart disease are advised to stop using probiotics before dental surgery or other invasive gastrointestinal procedures.

Immunodeficiency: use with caution

Lactobacillus-based preparations could cause pathogenic colonization, particularly in immunocompromised patients.